
Could A Vaccine You Probably Already Have Protect Against Gonorrhea?
There’s potential good news in gonorrhea prevention as a series of studies suggests that certain meningococcal B (MenB) vaccines can reduce the risk of gonorrhea.
The World Health Association (WHO) recently declared a global health emergency amid rising cases of mpox. The current outbreak, which began in the Democratic Republic of Congo (DCR), is caused by a deadlier form of the virus than the one that spread throughout the world in 2022. Cases have been found in at least thirteen African nations. The first cases outside of Africa were recently reported in Sweden in Thailand in men had traveled to the area.
Mpox is related to the smallpox virus. Researchers have identified two main types of the virus called clade I and clade II. The worldwide outbreak in 2022 was caused by a clade II type which causes typically mild infections and has a fatality rate less than 1%. Most of the cases in that outbreak were among men who have sex with men.
The current outbreak in Africa is caused by clade I mpox which is more infectious, causes more serious illness, and has a fatality rate around 10%. Clade I mpox is endemic to the DRC, but until recently most cases were passed from animals to humans through butchering and eating. This newest outbreak seems to be caused by a new version of the virus that is spreading from person to person. Scientists are referring to this version as clade Ib.
In some places in Africa, the clade Ib virus appears to be spread between members of a household or through patient care when appropriate protective gear was not available. In these areas a high proportion of cases have been reported in children under the age of 15. In other areas, sexual transmission is most common. This is the first time that clade I mpox has been sexually transmitted, and most cases are being passed through heterosexual sex. Many cases have been observed in sex workers, truck drivers, and other transient workers.
This year, there have been over 17,000 infections and more than 500 deaths from mpox in central and eastern Africa, most of which have been in the DCR. The WHO is sounding the alarm in the hopes of creating a coordinated international response that could prevent this deadlier version from spreading globally. The head of International Health Regulation Emergency Committee put it this way:
“The current upsurge of mpox in parts of Africa, along with the spread of a new sexually transmissible strain of the monkeypox virus, is an emergency, not only for Africa, but for the entire globe. Mpox, originating in Africa, was neglected there, and later caused a global outbreak in 2022. It is time to act decisively to prevent history from repeating itself.”
The Centers for Disease Control and Prevention (CDC) say there is no immediate threat of clade I mpox in the United States because travel to the area is limited, but it is continuing to monitor the situation closely. Anyone who does travel to areas with outbreaks should avoid contact with people who are sick (especially people who have rashes or lesions) and should stay away from wild animals and “bushmeat.”
The CDC has told clinicians to be on the lookout for symptoms of mpox. In the last outbreak, mpox blisters appeared on the genitals and were often misdiagnosed as herpes or syphilis. Clinicians should ask patients presenting with possible mpox symptoms whether they or any of their partners have traveled to DRC or other areas in eastern and central Africa.
It’s also important to remember that there are still cases of clade II mpox in the United States though numbers are far lower than they were in 2022. During the peak of that outbreak there were 11,000 cases diagnosed each month. So far in 2024, there have only been 1,122 cases reported.
Most of the cases continue to be among people at higher risk for mpox who had not been vaccinated. The CDC recommend the JYNNEOS vaccine for:
In addition to suggesting everyone who fit these criteria get vaccinated, the CDC has put out mpox-specific safer sex guidelines which remind people that the virus is spread through close face-to-face contact as well as contact with blisters and any fabric that has touched the blisters.
Changes in behavior among gay, bisexual, trans, and other MSM—such as reducing anonymous sex, having less skin-to-skin contact, and washing all bedding immediately—were credited with keeping the virus in check during the major outbreak.
While the risk of a new mpox epidemic remains low in the U.S., recent experiences with pandemics—both COVID and mpox—should remind us that both public health officials and individuals need to should stay informed and prepared.
There’s potential good news in gonorrhea prevention as a series of studies suggests that certain meningococcal B (MenB) vaccines can reduce the risk of gonorrhea.
There is new guidance on pain management for IUD insertion and acknowledgement that providers often underestimate the pain patients feel during their procedures.
The FDA just approved the Teal Wand, a self-collection device for HPV testing that does not require a speculum exam or even a trip to the doctor’s office. People can collect their own sample at home and send it to a lab for analysis.
The results of large-scale study of HPV suggest that one shot of the vaccine may be enough to protect young people from HPV and related issues like cervical cancer.
About 1.6 million cases of chlamydia and 600,000 cases of gonorrhea are diagnosed in the United Sates each year. A new study suggests that these patients may not be following through with STI treatment or getting the right antibiotics.
A clinical trial of a new antibiotic found that it works just as well as a current drug regimen for treating gonorrhea infections. This is important because the bacteria that causes gonorrhea has become resistant to most existing antibiotics.
There’s new research to suggest that the birth control pill can protect female athletes from ACL tears which is one of the most common knee injuries. While this may sound far-fetched, the science behind it is very interesting.
The FDA just approved a new, fully at-home test for chlamydia, gonorrhea, and trichomoniasis. The tests, which is only for women, will be available without a prescription. Users can collect their own sample and have results in less than 30 minutes.
ASHA believes that all people have the right to the information and services that will help them to have optimum sexual health. We envision a time when stigma is no longer associated with sexual health and our nation is united in its belief that sexuality is a normal, healthy, and positive aspect of human life.
ABOUT
GET INVOLVED
ASHA WEBSITES
GET HELP
© 2025 American Sexual Health Association